EGFR and metastatic colorectal cancer: In conclusion, this study suggests that the severity of AfR caused by anti‐EGFR antibodies varies with facial skin type, and that facial skin with a high number of enlarged pores is a possible marker for predicting AfR risk due to anti‐EGFR antibody therapy and better therapeutic effects for RAS wild‐type metastatic colorectal cancer.